Symptom-Producing Mechanisms in ME/CFS

Understanding ME/CFS requires distinguishing between mechanisms that limit capacity—impaired mitochondrial function, reduced cerebral blood flow, metabolic rigidity—and mechanisms that produce symptoms: the biological processes that generate the lived experience of fatigue, cognitive impairment, pain, and malaise. This chapter focuses on the latter. The distinction matters clinically: a patient may have preserved aerobic capacity yet be driven into exhaustion by powerful neurochemical signals that the brain interprets as danger; conversely, restoring energy metabolism without addressing symptom-signalling pathways would still leave the patient disabled.

The sections that follow trace symptom production from overarching integrative frameworks (sickness behavior, 15.1–15.2), through specific neurochemical generators (adenosine, cytokines, serotonin, melatonin, microglia, kynurenine, mast cells, 15.3–15.9), into systems-level amplifiers (glymphatic failure, central sensitization, oxidative stress, metabolic danger signals, endocannabinoid deficiency, interoceptive dysregulation, 15.10–15.15), and finally to integrated models, patient phenotypes, and therapeutic implications (15.16–15.19).

NoteChapter Roadmap: How to Use This Chapter

For patients: read the capacity-limiting vs symptom-producing distinction to understand why you can feel exhausted beyond what energy tests show, and the sickness-behavior and orexin sections for the brain’s role in fatigue.

For caregivers: read the capacity-vs-symptom distinction to understand why the patient’s felt exhaustion may not match activity capacity. The neurochemical detail can be skimmed.

For clinicians: read the sickness-behavior, orexin, adenosine, and cytokine sections for the mechanism behind non-restorative sleep and the “tired but wired” state, and the medication sections (sleep agents) for prescribing implications. Note the glymphatic rationale for these agents is untested — base prescribing on the established sleep evidence, not the mechanistic claims.

For researchers: read the neurochemical-generator sections and their falsifiable predictions — several define drug-trial hypotheses in the orexin, adenosine, and kynurenine pathways.

1 Contents